Member Info for Hikikomori

Micky, the 3rd week in Nov was referring to the SIV.

We already know this has been completed.

It would be in true Hemo spirit for them to make what could be their biggest ever announcement when people are away on their holidays between Xmas and NY, for it to be lost in the ether and have the lowest possible impact.

If that video was your first introduction to the company, you likely wouldn’t be struck with a positive impression.

The science may be great, but both are poor communicators.

On top of that, Peter could at least wear a jacket. Yes, it’s an comms update for investors, however, you would dream of going to a business meeting/presentation looking like you had been dressed by a carer, and these videos should be treated no different. First impressions do count, and this was not one of professionalism.

Also, what is that chair, looks like something my late grandmother may have sat in back in the 80’s?

Can I trouble you for a signature for your life saving treatment sir?

Sorry, I’m a bit busy right now.

To be honest, the lack of trades is likely more to do with the fact many brokers won’t allow you to trade Hemo in their platforms today, rather than the SP having moved up due to consolidation.

Maybe you can call up to buy or sell, haven’t tried.

Don’t agree.

Cost of doing a trade would in many cases exceed what you could lose, which is a max of 399 shares, or £4 of stock.

Also, I think the plan is to reimburse those who lose shares due to the consolidation. It was mentioned in an RNS somewhere I’m sure.

Fully agree Andy, consolidation alone won’t stop it.

What will stop it, or at least significantly reduce it, is funding. The legitimate questions over how the company can progress, due to lack of capital, allow the price to be driven down.

Once that question is answered and the company has a clear pathway to progress trials (and other treatments in development) then the SP can begin to recover and maybe even flourish.

As many have already stated, the company believe that the consolidation will open up new funding options that weren’t previously available to them due to their penny stock status.

We shouldn’t have long to wait to find out anyway.

In simple terms, deferred shares are used in conjunction with convertible shares to ensure that there is no reduction of capital as a result of a consolidation.

I believe yesterday was the final day of the bio defence conference.

It’s a proposed 400:1 consolidation.

The SP should therefore be 400x the size of the SP at the time the consolidation takes place.

Somewhere between £4-5 would be my guess

And if we do see a JV or licensing along the way for CAR-T, then we can look forward to progressing CDX and CBR, which are arguably more valuable if they live up to their potential.

At that point, I may even leave my bedroom to celebrate with shareholders BHI

The last raise, whilst only 600k, was to a single investor, and even though they flipped the whole lot, the price didn’t fall below the placing price. That’s a positive for me, in that the market knows there is value above what they can raise at.

As the trial develops, assuming early data is positive, I expect a steady rise in the price.

Given Stage 1 may take up to 18 months perhaps (educated views welcome), I think we may need to raise more than £5m, but if we pass that milestone we are talking about a drug with a value measured in the 100’s of millions. Even with 100% dilution from here, that’s a huge return for current holders.

You can always rely on BHI to turn the conversation toward himself, thus inviting further bickering and pushing anything useful down the page as a result.

Well done BHI

With credit and thanks to Mrs India for sharing the below link, which discusses how CAR-T treatments have faired in clinical trials, compared to other types of treatments.

https://alliancerm.org/press-release/new-analysis-by-tufts-newdigs-shows-that-durable-cell-and-gene-therapies-have-substantially-higher-clinical-success-rates-than-other-treatments/

Seems there is much to be optimistic about.

As Hemo have signalled their intent to apply for Orphan Drug Status, hopefully this will be approved, as sponsors of an orphan drug can make use of expedited Food and Drug Administration (FDA) programs such as the Fast Track, Breakthrough Therapy, and Priority Review designations, as well as the Accelerated Approval pathway and unique grant funding opportunities, such as the Orphan Products Clinical Trials Grant program.

Have a good weekend all.

The question on links/data is also open to all, and may prove helpful to anyone who is weighing up their options and considering investing here.

Thanks

Hi kingpin,

You have stated it’s highly likely that phase 1 will be successful, but on what exactly are you basing this assumption?

Whilst I accept that phase 1 trials have a high success rate generally speaking, there is very little data I have been able to find that relates explicitly to CAR-T trials.

Are you able to share any links or data on CAR-T trials to support that its highly likely to be a success?

I’m pretty certain an NDA does not extend to reading.

You have clearly missed the original point

Whoknowswhy,

Try reading the RNS, then go on the internet and read up for yourself, rather than expecting everyone else to do the work for you.

You may need to utilise your brain though, so that may be a bit of an obstacle for you, given you can’t seem to grasp basic maths or the ability to comprehend numbers that are literally in the RNS.

There is absolutely nothing anyone can post here that is going to change sentiment unfortunately, anything positive is completely drowned out by negativity.

The company have to communicate plans to the market in layman’s terms, and they need to do it fast.

Whilst there is still hope for Hemo and investors providing early results are good, the handling of this entire situation could not have been executed any worse.

Another disasterclass by Vlad

Ricky, give it a rest man for heaven's sake.

Your continuous posting of the same thing is not going to change anyone’s mind, you just appear unhinged at this point.

People are entitled to have their view and to feel let down by events on Friday.

Everyone has to make their own mind up now, and you repeating yourself over and over again is just pointless.